Dronedarone Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 400 mg
Reference Brands: Multaq (USA/EU)
Category:
Heart Disorder
Dronedarone hydrochloride is a class III antiarrhythmic medication used to maintain normal heart rhythm in adults with a history of atrial fibrillation or atrial flutter. It helps reduce the risk of hospitalization due to these rhythm disorders. The drug is given orally as a 400 mg tablet taken twice daily with food. It works by blocking multiple cardiac ion channels to stabilize electrical activity in the heart. Dronedarone is an alternative to amiodarone with a modified chemical structure aimed at reducing certain toxicities.
Dronedarone hydrochloride is available in Tablets
and strengths such as 400 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Dronedarone hydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Dronedarone hydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Dronedarone hydrochloride is a small‑molecule antiarrhythmic medication indicated primarily for adults with a history of paroxysmal or persistent atrial fibrillation or atrial flutter who are in normal sinus rhythm and at risk of recurrence. It is used to help maintain normal heart rhythm and reduce the risk of hospitalization due to arrhythmia. Dronedarone belongs to the class III antiarrhythmic group and exhibits multichannel blocking effects on potassium, sodium, and calcium channels, and has additional antiadrenergic properties. Compared with its related drug amiodarone, dronedarone lacks iodine moieties, which is intended to reduce the risk of thyroid and pulmonary toxicities associated with amiodarone. The medication is supplied in 400 mg film‑coated tablets, typically taken twice daily with meals to improve absorption. While it can be effective in rhythm control, dronedarone must be used cautiously due to potential side effects, including liver injury and interactions with other medications. It is contraindicated in certain patients, such as those with severe heart failure or permanent atrial fibrillation. In the United States, it is marketed under the brand Multaq, and similar branded and generic forms are available in the European Union and United Kingdom.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing